共 50 条
Cost-effectiveness of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) testing and isolation strategies in nursing homes
被引:2
|作者:
Bartsch, Sarah M.
[1
,2
,3
]
Weatherwax, Colleen
[1
,2
,3
]
Martinez, Marie F.
[1
,2
,3
]
Chin, Kevin L.
[1
,2
,3
]
Wasserman, Michael R.
[4
,5
]
Singh, Raveena D.
[6
]
Heneghan, Jessie L.
[1
,2
,3
]
Gussin, Gabrielle M.
[6
]
Scannell, Sheryl A.
[1
,2
,3
]
White, Cameron
[1
,2
,3
]
Leff, Bruce
[7
]
Huang, Susan S.
[6
]
Lee, Bruce Y.
[1
,2
,3
,8
]
机构:
[1] CUNY, Ctr Adv Technol & Commun Hlth CATCH, Grad Sch Publ Hlth & Hlth Policy, New York, NY 10027 USA
[2] CUNY, Publ Hlth Informat Computat & Operat Res PHICOR, Grad Sch Publ Hlth & Hlth Policy, New York, NY 10027 USA
[3] CUNY, Artificial Intelligence Modeling Informat Nutr Gui, Grad Sch Publ Hlth & Hlth Policy, New York, NY 10027 USA
[4] Los Angeles Jewish Home, Reseda, CA USA
[5] Calif Assoc Long Term Care Med, Santa Clarita, CA USA
[6] Univ Calif Irvine, Div Infect Dis, Sch Med, Irvine, CA USA
[7] Johns Hopkins Univ, Ctr Transformat Geriatr Res, Div Geriatr Med, Sch Med, Baltimore, MD USA
[8] CUNY, New York City Pandem Response Inst PRI, Grad Sch Publ Hlth & Hlth Policy, New York, NY 10027 USA
基金:
美国医疗保健研究与质量局;
关键词:
COVID-19;
EFFICACY;
OUTCOMES;
D O I:
10.1017/ice.2024.9
中图分类号:
R1 [预防医学、卫生学];
学科分类号:
1004 ;
120402 ;
摘要:
Objective: Nursing home residents may be particularly vulnerable to coronavirus disease 2019 (COVID-19). Therefore, a question is when and how often nursing homes should test staff for COVID-19 and how this may change as severe acute respiratory coronavirus virus 2 (SARS-CoV-2) evolves.Design: We developed an agent-based model representing a typical nursing home, COVID-19 spread, and its health and economic outcomes to determine the clinical and economic value of various screening and isolation strategies and how it may change under various circumstances.Results: Under winter 2023-2024 SARS-CoV-2 omicron variant conditions, symptom-based antigen testing averted 4.5 COVID-19 cases compared to no testing, saving $191 in direct medical costs. Testing implementation costs far outweighed these savings, resulting in net costs of $990 from the Centers for Medicare & Medicaid Services perspective, $1,545 from the third-party payer perspective, and $57,155 from the societal perspective. Testing did not return sufficient positive health effects to make it cost-effective [$50,000 per quality-adjusted life-year (QALY) threshold], but it exceeded this threshold in >= 59% of simulation trials. Testing remained cost-ineffective when routinely testing staff and varying face mask compliance, vaccine efficacy, and booster coverage. However, all antigen testing strategies became cost-effective (<=$31,906 per QALY) or cost saving (saving <=$18,372) when the severe outcome risk was >= 3 times higher than that of current omicron variants.Conclusions: SARS-CoV-2 testing costs outweighed benefits under winter 2023-2024 conditions; however, testing became cost-effective with increasingly severe clinical outcomes. Cost-effectiveness can change as the epidemic evolves because it depends on clinical severity and other intervention use. Thus, nursing home administrators and policy makers should monitor and evaluate viral virulence and other interventions over time.
引用
收藏
页码:754 / 761
页数:8
相关论文